Screen for tau-focused drugs that inhibit tau toxicity
Project/Area Number |
23790313
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
General pharmacology
|
Research Institution | National Center for Geriatrics and Gerontology (2012-2013) The Institute of Physical and Chemical Research (2011) |
Principal Investigator |
SOEDA Yoshiyuki 独立行政法人国立長寿医療研究センター, 分子基盤研究部, 研究員 (10553836)
|
Project Period (FY) |
2011 – 2013
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
Keywords | タウ凝集阻害剤 / タウ / 凝集 / イソプロテレノール / スクリーニング / 化合物 / 認知症 |
Research Abstract |
In an aging society, the number of people with dementia has increased. Since Alzheimer's disease and a part of frontotemporal lober degeneration (FTLD-tau) have abnormal tau pathology in brain, these are called Tauopathy. Previously results showed that abnormal tau has been involved in development of cognitive dysfunction suggesting that tau-focused drug might be valuable in therapy for Tauopathy. This study screened low molecular compounds that were targeted to tau, and obtained two evidences. First, novel compounds were identified as tau aggregation inhibitor, and inhibited tau cytotoxicity. Second, inhibitory mechanism of tau aggregation by the compounds was elucidated. These data will initiate clinical study and research for drug discovery based on the mechanism. Thus, the study provided scientific basic outcomes, which may be contributed to development of cognitive therapies for dementia.
|
Report
(4 results)
Research Products
(13 results)
-
-
-
-
[Presentation] タウ凝集阻害剤2013
Author(s)
添田義行
Organizer
タウ研究ミーティング
Place of Presentation
愛知県大府市
Year and Date
2013-08-09
Related Report
Invited
-
-
-
-
-
-
-
-
-